ISPOR Europe 2025! – Healthcare Economist
Excited to have finished day 1 at ISPOR Europe in Glasgow, Scotland.
Come check out my session on Tuesday with Tiago Beck at 11:30-12:00pm.
Robots and Health – Healthcare Economist
An interesting finding from Liu, Wang, Jin and Lu (2025):
While the labor market effects of industrial robots have been extensively studied, their broader health implications, particularly.
How should managed care pharmacists work improve patient engagement? – Healthcare Economist
While for years patient engagement has been seen as a valuable, starting in 2026 this will be a legal mandate.
Plans offering essential health.
What is the impact of implementing GRACE on health care budgets? – Healthcare Economist
Generalized risk-adjusted cost effectiveness analysis (GRACE) abandons the assumption of risk neutrality held by traditional cost effectiveness analysis (TCEA). While this sounds like a very technical issue,.
2025 Employer Health Benefits Survey – Healthcare Economist
The 2025 Employer Health Benefits Survey came out last week. Here are some key findings:
Premium costs
The average annual premiums for employer-sponsored health insurance in 2025 are $9,325 for single.
Health Wonk Review is Back! – Healthcare Economist
Special thanks to Joe Paduda to bringing back the best review of health wonkery on the web. Joe writes:
Way back in the day Julie Ferguson.
Change to UK Rare Disease Approval Process – Healthcare Economist
The Times reports that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is revising it’s approach to how it approves new medicines that treat rare diseases. .
Where Are We and Where Are We Going?” – Healthcare Economist
That is the title of my Fast Facts presentation at ISPOR Europe at 11:30 GMT on Tuesday, November 11 with Tiago Beck. If you’re in Glasgow next week,.
How often do US commercial health plans apply coverage restrictions to cell and gene therapies? – Healthcare Economist
That is the question a new paper by Chambers et al. (2025) aims to answer. The authors use data from the Specialty Drug Evidence and Coverage (SPEC).